Adult Eczema in Houston: New Biologics and JAK Inhibitors

This article is educational and does not replace an evaluation by a board-certified dermatologist. If your eczema is not controlled, please book a visit.

If your eczema has outlasted every drugstore cream and every round of hydrocortisone, the useful question is no longer which moisturizer to try. It is whether it is time for a different category of treatment. Adult atopic dermatitis has been reshaped over the last decade by dupilumab, three newer antibodies targeting interleukin-13 and interleukin-31, and both topical and oral JAK inhibitors. Here is where each one sits, what the Phase 3 data show, and what the risks are, including a boxed warning that deserves a straight reading. Atopic dermatitis is chronic and relapsing; nothing below cures it, and the goal is durable control.

Adult eczema is not childhood eczema that stayed

How adult-onset atopic dermatitis is diagnosed, and what we look for

Adult atopic dermatitis frequently looks nothing like the textbook flexural rash of a toddler. Common adult patterns include head-and-neck dermatitis, hand and eyelid involvement, nummular (coin-shaped) plaques, prurigo-like papules, and diffuse lichenification rather than acute weeping. Diagnosis remains clinical: itch is an essential feature, combined with eczematous morphology, a chronic relapsing course, and a personal or family history of atopy. No blood test establishes it, and a raised total IgE neither confirms nor excludes it. What matters more in adults is the differential: allergic contact dermatitis, which requires patch testing; psoriasis; scabies; drug eruption; and cutaneous T-cell lymphoma, which can imitate treatment-resistant adult eczema for years. Any adult with atypical or refractory disease should be biopsied or patch tested rather than escalated blindly.

On exam we read the secondary changes that show how long the itch-scratch cycle has run: excoriations, lichenified plaques with accentuated skin markings, fissuring on the hands, plus xerosis, Dennie-Morgan infraorbital folds, hyperlinear palms, and keratosis pilaris. Honey-colored crust, pustules, or worsening despite good adherence suggest bacterial superinfection. Presentation also differs by skin tone: in skin of color, atopic dermatitis is often more papular and follicular, erythema reads violaceous or greyish rather than red, and post-inflammatory hyperpigmentation is frequently the main complaint. Both facts cause severity to be underestimated.

How Houston's climate complicates atopic dermatitis

Humidity, sweat, and Staphylococcus aureus

Average relative humidity in Houston runs near 75% year-round (NOAA). High ambient humidity slows water loss from the skin, which in isolation helps. What follows it does not. Heat and humidity drive sweating, and sweat is a direct itch trigger in atopic dermatitis: it raises skin surface pH, deposits irritant salts, and pools under clothing where skin is already occluded, restarting the itch-scratch cycle. Warm, moist, barrier-compromised skin also favors Staphylococcus aureus, which colonizes lesional atopic skin far more heavily than healthy skin and whose density tracks with severity. A Houston flare often has an infectious component, and treating inflammation without addressing colonization stalls. Our guide to eczema triggers in humid climates goes deeper.

Indoor air, mold, and a year-round allergen load

Houstonians spend most of the year in air conditioning, so most exposure hours are to indoor air. Dust mite populations thrive in humid indoor environments, and dust mite sensitization is common in adults with atopic dermatitis. The Gulf Coast also carries a high mold burden, and any history of water intrusion after a storm raises indoor spore exposure. Outdoors there is no hard freeze to reset the pollen calendar, so tree, grass, and weed seasons overlap into a nearly continuous load, and Houston patients rarely get the seasonal remission patients in colder climates describe.

What moderate to severe actually means

EASI, SCORAD, and quality-of-life measures in clinic

These terms map to scored instruments. The Eczema Area and Severity Index (EASI) grades erythema, edema and papulation, excoriation, and lichenification across four body regions weighted by involved area, on a 0 to 72 scale, so EASI-75 means a 75% reduction from baseline. SCORAD adds patient-reported itch and sleep loss. The vIGA-AD is a 0 to 4 static scale on which success usually means reaching 0 or 1 with at least a two-grade improvement. Clinically the threshold for a systemic conversation is not a number alone: it is disease uncontrolled despite optimized topical therapy, extensive involvement, or limited involvement with severe itch, disrupted sleep, or impairment of the hands or face.

Treatment decisions depend on your individual skin, medical history, and goals. The information below describes how dermatologists evaluate options; it is not a prescription or a recommendation for any specific person.

First-line control that still works

Emollients and barrier repair

Every systemic therapy below is layered on top of barrier care, not instead of it: a thick, ceramide-containing cream or ointment at least twice daily and within a few minutes of bathing, short lukewarm showers, and a gentle non-soap cleanser. The AAD's atopic dermatitis guidelines give moisturizers a strong recommendation and also address dilute bleach baths in moderate to severe disease with recurrent infection (AAD, 2023). This step is not optional.

Topical corticosteroids and the potency ladder

Topical corticosteroids remain the anti-inflammatory backbone of flare control, and the skill is matching potency to site. Low-potency agents such as hydrocortisone go on the face, eyelids, neck, and flexures; mid-potency agents such as triamcinolone acetonide 0.1% suit the trunk and extremities; high-potency agents are reserved for thick lichenified plaques, palms, and soles. Twice-daily application controls a flare, and proactive maintenance to previously affected sites two days per week reduces relapse. Prolonged inappropriate use causes atrophy, striae, telangiectasia, and pigment change, and superpotent use over large areas can suppress the HPA axis.

Topical calcineurin inhibitors

Tacrolimus ointment and pimecrolimus cream block calcineurin-dependent T-cell activation. Because they do not cause skin atrophy, they are particularly useful on the face, eyelids, neck, and flexures and for long-term maintenance where steroids are a poor fit. Burning or stinging is common in the first several days and usually settles. Both carry an FDA boxed warning regarding a theoretical malignancy risk; long-term observational data have not established a causal link and the AAD continues to recommend them, but the warning is on the label and you should hear it from your dermatologist.

Newer non-steroidal topicals for daily use

Ruxolitinib cream (Opzelura), a topical JAK1 and JAK2 inhibitor

Ruxolitinib cream inhibits JAK1 and JAK2 signaling in the skin. In the Phase 3 TRuE-AD program, investigator-assessed treatment success at week 8 was reached by 53.8% of patients on the 1.5% cream twice daily versus 15.1% on vehicle, and 51.3% versus 7.6% in the second trial. It is approved for short-term, non-continuous use in mild to moderate disease in non-immunocompromised patients not adequately controlled by other topical prescriptions, with label limits on body surface area and quantity. It carries the same class boxed warning as oral JAK inhibitors, discussed below, despite being applied to the skin.

Roflumilast cream (Zoryve), a topical PDE4 inhibitor

Roflumilast cream inhibits phosphodiesterase-4, raising intracellular cyclic AMP and damping inflammatory cytokine production. In the pooled Phase 3 INTEGUMENT-1 and INTEGUMENT-2 results, vIGA-AD success at week 4 was reached by 31.3% of patients on roflumilast cream 0.15% once daily versus 14.1% on vehicle. It is steroid-free, once daily, carries no boxed warning, and is a reasonable choice for maintenance on sensitive sites or for patients who want to reduce steroid exposure.

Crisaborole (Eucrisa) and tapinarof (Vtama)

Crisaborole 2% ointment is an earlier topical PDE4 inhibitor used twice daily in mild to moderate disease; application-site burning is its main tolerability limitation. Tapinarof 1% cream works through a different mechanism, as an aryl hydrocarbon receptor agonist. In the Phase 3 ADORING trials, vIGA-AD success at week 8 was reached by 45.4% versus 13.9% on vehicle in one trial and 46.4% versus 18.0% in the other, with folliculitis and headache as the notable adverse events.

Systemic biologics for moderate to severe disease

All four below are injectable antibodies that block specific cytokine signals. None requires routine laboratory monitoring, which is a meaningful practical difference from the oral agents that follow.

Dupilumab (Dupixent), targeting IL-4 receptor alpha

Dupilumab binds the shared IL-4 receptor alpha subunit and therefore blocks both IL-4 and IL-13 signaling, the central type 2 inflammatory axis in atopic dermatitis. In the pivotal LIBERTY AD SOLO 1 and SOLO 2 monotherapy trials, an IGA of 0 or 1 at week 16 was achieved by 38% and 36% of patients versus 10% and 8% on placebo, and EASI-75 by 51% and 44% versus 15% and 12% (Simpson et al., NEJM 2016). Dosed subcutaneously every two weeks after a loading dose, it has the longest real-world safety record of the four and needs no routine lab monitoring. Its characteristic adverse events are injection-site reactions, conjunctivitis, and in a minority a head-and-neck erythema needing specific management.

Tralokinumab (Adbry) and lebrikizumab (Ebglyss), targeting IL-13

Both neutralize IL-13 specifically rather than blocking the shared receptor. Tralokinumab reached EASI-75 at week 16 in roughly 25% and 33% of patients versus about 13% and 11% on placebo in the ECZTRA 1 and ECZTRA 2 monotherapy trials, with higher rates when combined with topical corticosteroids (Wollenberg et al., British Journal of Dermatology, 2021), and responders can move from every two weeks to every four. Lebrikizumab, a higher-affinity IL-13 antibody, reached EASI-75 at week 16 in 58.8% and 52.1% versus 16.2% and 18.1% on placebo in ADvocate1 and ADvocate2 (Silverberg et al., NEJM 2023), and moves to once-monthly maintenance after induction, which matters more to adherence than it sounds. Conjunctivitis is worth discussing with either.

Nemolizumab (Nemluvio), targeting IL-31 receptor alpha

Nemolizumab blocks the receptor for IL-31, the cytokine most directly implicated in itch signaling, which makes it mechanistically distinct from the three above. In the Phase 3 ARCADIA 1 and ARCADIA 2 trials, given with concomitant topical therapy, EASI-75 at week 16 was reached by 44% versus 29% and 42% versus 30% on placebo (Silverberg et al., Lancet 2024). The reason to consider it is not a higher clearance number but the itch signal, so it is worth discussing when relentless itch and sleep loss dominate.

Oral JAK inhibitors and the FDA boxed warning

Upadacitinib (Rinvoq) and abrocitinib (Cibinqo)

Both are once-daily oral selective JAK1 inhibitors, and both act faster and reach higher response rates than any biologic in this space. In Measure Up 1 and Measure Up 2, upadacitinib produced EASI-75 rates at week 16 in the range of roughly 60% to 80% depending on dose and trial, versus 13% to 16% on placebo. In JADE MONO-1 and JADE MONO-2, abrocitinib reached EASI-75 in 40% and 44% of patients at 100 mg and 62% and 61% at 200 mg, versus 12% and 10% on placebo. Itch often improves within days rather than weeks. Both require baseline and ongoing laboratory monitoring, including complete blood count, hepatic panel, and lipids, plus tuberculosis screening before starting.

What the boxed warning actually says

The FDA applies a class boxed warning to JAK inhibitors, and it should be read in full rather than summarized away. It covers serious infections, including tuberculosis and invasive fungal and other opportunistic infections; mortality, based on a higher rate of all-cause death observed with a JAK inhibitor compared with TNF blockers in a rheumatoid arthritis trial; malignancies, including lymphoma and, in current or past smokers, lung cancer; major adverse cardiovascular events, meaning cardiovascular death, myocardial infarction, and stroke; and thrombosis, including deep vein thrombosis, pulmonary embolism, and arterial thrombosis. Much of the underlying data comes from an older rheumatoid arthritis population with cardiovascular risk factors rather than from atopic dermatitis trials, and that context is legitimately part of the discussion. It does not remove the warning. A responsible conversation covers your age, smoking history, cardiovascular and clotting risk, and cancer history before a prescription is written, and the same class warning appears on the label of ruxolitinib cream.

How we sequence therapy at Bayou City Dermatology

The order matters more than the menu. We start by optimizing what is available: barrier repair, correctly matched corticosteroid potency, proactive twice-weekly maintenance, treatment of secondary infection, and patch testing when contact allergy could be driving apparent treatment failure. Many adults labeled refractory are undertreated, or are reacting to something in their routine. When optimized topical therapy genuinely fails, a biologic is the usual next step for most adults, since none requires lab monitoring; within that group, dominant itch points toward nemolizumab and dosing convenience toward lebrikizumab. An oral JAK inhibitor is the better choice when control is needed quickly, when biologics have failed or are not tolerated, or when injections are unacceptable, following an explicit risk assessment and baseline labs. Our comprehensive guide to eczema management and our allergies and atopic dermatitis page cover the day-to-day side.

Frequently Asked Questions

Which biologic is best for adult eczema?

There is no single best biologic. Dupilumab has the longest real-world track record and blocks both IL-4 and IL-13 signaling. Lebrikizumab reported the highest EASI-75 rates of the group in Phase 3 and moves to monthly maintenance. Tralokinumab targets IL-13 with flexible dosing intervals. Nemolizumab targets the IL-31 itch pathway. Head-to-head data are limited, so selection depends on your symptom pattern, prior response, comorbidities such as asthma, dosing preference, and coverage.

Do JAK inhibitors work for eczema?

Yes, and they work quickly. Oral upadacitinib and abrocitinib produced the highest EASI-75 rates and the fastest itch reduction of any systemic option in Phase 3, often with relief within days. They also carry an FDA class boxed warning covering serious infections, mortality, malignancy, major adverse cardiovascular events, and thrombosis, and they require baseline and ongoing lab monitoring plus tuberculosis screening. That trade-off is why the decision belongs with a dermatologist who has reviewed your history.

How much does dupilumab cost with insurance?

What you pay is rarely the list price. Most commercially insured patients pay a fraction of it after benefits apply, and the manufacturer runs a copay assistance program for eligible patients; Medicare, Medicaid, and marketplace plans work differently. Prior authorization is nearly always required, and denials are frequently overturned on appeal with documentation of failed topical therapy. Ranges vary widely by plan, so the practical step is a benefits check before starting.

Is topical steroid withdrawal real?

It is described in the medical literature, most often as topical steroid withdrawal or red skin syndrome, and reported after prolonged use of potent topical steroids, particularly on the face and genital skin. It is less well characterized than conditions with defined diagnostic criteria and is easy to confuse with a flare of the underlying eczema, which is why it should be assessed in person rather than self-diagnosed. It is also not a reason to stop a prescribed steroid abruptly.

Does Houston humidity make eczema better or worse?

Both mechanisms are real, and for most of our patients the net effect is worse. High humidity does slow water loss through the skin, which can help dryness. But heat and humidity also drive sweating, a direct itch trigger, they favor Staphylococcus aureus colonization on already-compromised skin, and Houston's indoor dust mite and mold burden plus an almost continuous pollen calendar remove the seasonal break patients in colder climates get.

Book a dermatology evaluation

If your eczema is keeping you awake, spreading beyond what topicals control, or affecting your hands, face, or work, there is far more available now than there was five years ago, and the right next step depends on an exam rather than an article. Book a dermatology evaluation at Bayou City Dermatology. If heat and humidity aggravate other conditions for you, our articles on rosacea flares in Houston summer and hidradenitis suppurativa in Houston summer may help.

References

1. American Academy of Dermatology. Guidelines of care for the management of atopic dermatitis. aad.org
2. NIAMS. Atopic dermatitis. niams.nih.gov
3. Simpson EL, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. NEJM. 2016;375(24):2335-2348. nejm.org
4. Wollenberg A, et al. Tralokinumab for moderate-to-severe atopic dermatitis (ECZTRA 1 and 2). Br J Dermatol. 2021. onlinelibrary.wiley.com
5. Silverberg JI, et al. Two phase 3 trials of lebrikizumab for moderate-to-severe atopic dermatitis. NEJM. 2023;388(12):1080-1091. nejm.org
6. Silverberg JI, et al. Nemolizumab with concomitant topical therapy (ARCADIA 1 and 2). Lancet. 2024. sciencedirect.com
7. Papp K, et al. Ruxolitinib cream for atopic dermatitis (TRuE-AD1 and TRuE-AD2). JAAD. 2021. sciencedirect.com
8. Roflumilast cream 0.15% for atopic dermatitis (INTEGUMENT-1 and 2). JAMA Dermatology. 2024. pubmed.ncbi.nlm.nih.gov
9. Tapinarof cream 1% once daily in atopic dermatitis: the ADORING trials. JAAD. 2024. jaad.org
10. Bieber T, et al. Abrocitinib versus placebo or dupilumab for atopic dermatitis. NEJM. 2021;384(12):1101-1112. nejm.org
11. FDA. Prescribing information and boxed warnings for Dupixent, Adbry, Ebglyss, Nemluvio, Opzelura, Zoryve, Rinvoq, and Cibinqo. accessdata.fda.gov
12. NOAA and National Weather Service Houston/Galveston. Humidity and climate data. weather.gov/hgx